Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.
about
Management of endocrine disease: Secondary osteoporosis: pathophysiology and managementDiagnostic performance of osteocalcin measurements in patients with endogenous Cushing's syndrome.Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.Glucocorticoid-induced osteoporosis: lessons from Cushing's syndrome.The risk factors for fractures and trabecular bone-score value in patients with endogenous Cushing's syndrome.Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing's disease.Diabetes in Cushing Disease.The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes.Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.BclI polymorphism of the glucocorticoid receptor gene is associated with increased bone resorption in patients on glucocorticoid replacement therapy.Diagnostic performance of a newly developed salivary cortisol and cortisone measurement using an LC-MS/MS method with simple and rapid sample preparation.Bone resorption is suppressed immediately after the third and fourth days of multiday cycling but persistently increased following overnight recovery.The CRH-Transgenic Cushingoid Mouse Is a Model of Glucocorticoid-Induced Osteoporosis
P2860
Q26998249-40F38E47-3B3C-45EA-87E3-52482F73BE25Q37007565-9F1C23E7-9476-473A-A4F8-255CA219FC81Q38015162-0C611217-ADA8-4943-9AC5-486AB45E142DQ38085698-246E163A-5153-408B-9A76-57CB75BC3D9FQ38420184-0EF45C13-B804-4AD5-8224-6B43670ACB44Q38603477-D6DE78B1-44F0-4DC8-8085-4F093C4F5C79Q39212408-0FF6528A-35E7-4DE8-96A5-0B1773CD42DCQ40828040-D117975B-40A6-4FA1-801A-7D46909F7087Q45797594-187F3360-96E1-4486-B574-FCD945FCF467Q48908924-7873DABE-0A1B-41FA-B8FB-B99E2C58EA61Q51345508-9EB60792-EC72-4ADD-9A67-3AB9FA9931F3Q52886154-0401F940-19AF-43DB-9C3B-35DF68B7EFBEQ53107972-7A2ABB77-264D-48F0-97DB-69942D1E6FB8Q54378765-80E6F9A7-2E78-472A-B65C-8F4AFD5E6B45Q57153114-2B6D5D57-5A29-4690-8E75-C88817C631A9
P2860
Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Bone turnover in patients with ...... nd after successful treatment.
@en
Bone turnover in patients with ...... nd after successful treatment.
@nl
type
label
Bone turnover in patients with ...... nd after successful treatment.
@en
Bone turnover in patients with ...... nd after successful treatment.
@nl
prefLabel
Bone turnover in patients with ...... nd after successful treatment.
@en
Bone turnover in patients with ...... nd after successful treatment.
@nl
P2093
P2860
P1476
Bone turnover in patients with ...... nd after successful treatment.
@en
P2093
A Szappanos
P2860
P2888
P304
P356
10.1007/S00198-009-0978-Y
P407
P50
P577
2009-06-10T00:00:00Z
P5875
P6179
1017317807